A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - INDUCE-4

GlaxoSmithKline Research & Development Ltd0 个研究点目标入组 116 人开始时间: 2020年9月10日最近更新: 2023年11月6日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: GlaxoSmithKline Research & Development Ltd
入组人数: 116

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
•2. Male or female, age =18 years; at the time consent is obtained (minimum age requirement per local regulatory requirements)
•3. Histological or cytological documentation of HNSCC that was diagnosed as recurrent or metastatic and considered incurable by local therapies
•4. Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx the exception of systemic therapy completed > 6 months prior if given as part of multimodal treatment for locally advanced disease and no disease progression/recurrence within 6 months of the completion of curatively intended systemic treatment)
•6. Measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1 guidelines
•7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
•8. Adequate organ function as defined in Table 3 of the study protocol
•9. Life expectancy of at least 12 weeks
•10. Female participants: must not be pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin [ß-hCG] test in females of reproductive potential; for further details refer to Section 10.4), not breastfeeding, and at least one of the following conditions apply:
•a) Not a woman of childbearing potential (WOCBP) as defined in Section 10.4.1. of the study protocol
•b) A WOCBP who agrees to use a highly effective method of birth control from 30 days prior to randomization and for at least 120 days after the last dose of study treatment (Note: duration of contraceptive use after last dose of chemotherapy must be consistent with local requirements; however, the minimum duration is 180 days after last dose of chemotherapy). Refer to
•Section 10.4.2 of the study protocol for permitted contraceptive methods; contraceptive use
•should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•c) The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy
•11. Male participants with female partners of child-bearing potential: must agree to use a highly effective contraception while receiving study treatment and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period (Note: duration of contraceptive use after last dose of chemotherapy must be consistent with local requirements; however, the minimum duration is 180 days after last dose of chemotherapy). Refer to Section 10.4.2 of the study protocol for permitted contraceptive methods; contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in
•clinical studies.
•12. Provide tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) acquired within 2 years prior to randomization for PD-L1 immunohistochemistry (IHC) testing by central laboratory. A fresh tumor biopsy, using a procedure that is safe for the participant on a lesion not previously irradiated (unless lesion progressed) will be required if previously acquired tumor tissue (i.e., archival tumor tissue) was acquired > 2 years or is
•unavailable//unsuitable for PD-L1 testing.
•13. Have PD-L1 IHC CPS status by central laboratory testing (refer to

排除标准

•1. Prior therapy with an anti-PD-1/L1/L2, anti-ICOS directed agent
•2. Systemic approved or investigational anticancer therapy within 30 days or 5 half lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the date of randomization
•3. Has high risk of bleeding (examples include but are not limited to tumors encasing or infiltrating a major vessel [i.e., carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as a fistula, significant cavitary lesions, prior history of hemorrhage [60 days])
•NOTE: following principal investigator consultation with the GSK Medical Monitor, certain cases may be approved by the GSK Medical Monitor upon review of the case (this review may include a requirement to provide images)
•4. Active tumor bleeding
•5. Grade 3 or Grade 4 hypercalcemia
•6. Major surgery 28 days prior to randomization. Participants must have also fully recovered from any surgery (major or minor) and/or its complications before randomization
•7. Toxicity from previous anticancer treatment that includes:
•a. Grade 3/Grade 4 toxicity considered related to prior immunotherapy and that led to treatment discontinuation
•b. Toxicity related to prior treatment that has not resolved to =Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be =Grade 2)
•8. Received transfusion of blood products (including platelets or red blood cells) or
•administration of colony stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, recombinant erythropoietin) within 14 days prior to randomization
•9. Central nervous system (CNS) metastases, with the following exception:
•Participants with asymptomatic CNS metastases who are clinically stable and have no requirement for steroids for at least 14 days prior to randomization
•Note: Participants with carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical stability
•10. Invasive malignancy or history of invasive malignancy other than disease under
•study within the last 3 years, except as noted below:
•a. Any other invasive malignancy for which the participant was definitively treated, has been disease-free for =3 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted
•malignancy, may be included in this clinical study
•b. Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma
•c. Low-risk early stage prostate cancer defined as follows: Stage T1c or T2a with a Gleason score = 6 and prostatic-specific antigen (PSA) <10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to randomization
•11. Autoimmune disease (current or history; refer to Table 19) or syndrome that required systemic treatment within the past 2 years
•Note: Replacement therapies which include physiological doses of corticosteroids
•for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.
•12. Has a diagnosis of immunodeficiency or is receiving systemic steroids (>10 mg oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to randomization
•a) Physiologic doses of corticosteroids for treatment o

研究者

发起方

GlaxoSmithKline Research & Development Ltd

相似试验

进行中（未招募）

1 期

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864

EUCTR2019-003981-42-DKGlaxoSmithKline Research & Development Ltd640

进行中（未招募）

1 期

EUCTR2019-003981-42-FRGlaxoSmithKline Research & Development Ltd116

进行中（未招募）

1 期

EUCTR2019-003981-42-GRGlaxoSmithKline Research & Development Ltd116

进行中（未招募）

1 期

EUCTR2019-003981-42-SEGlaxoSmithKline Research & Development Ltd116

进行中（未招募）

1 期

EUCTR2019-003981-42-ROGlaxoSmithKline Research & Development Ltd116